Background/Aims: The nonspecific clinical presentation of acute hepatitis A (AHA) mandates the detection of anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in the serum for obtaining a definitive diagnosis. However, IgM anti-HAV might not be present during the early phase of the disease. The aim of this study was to determine the optimal time for repeating the IgM anti-HAV test (HAV test) in AHA patients with a negative initial test. Methods: In total, 261 patients hospitalized with AHA were enrolled for this retrospective study. AHA was diagnosed when the test for IgM anti-HAV was positive and the serum alanine aminotransferase (ALT) level was ≥400 IU/L. Repeat HAV test was conducted after 1-2 weeks if the initial HAV test was negative but AHA was still clinically suspected. Results: The results of the initial HAV test were negative in 28 (10.7%) patients. The intervals from symptom onset to the initial-HAV-test day and from the peak-ALT day to the initial-HAV-test day were significantly shorter in the negative-initial-HAV-test group, but on multivariate analysis only the latter was significantly associated with negative results for the initial HAV test (β=-0.978; odds ratio [95% confidence interval]=0.376 [0.189-0.747]; P=0.005). The HAV test was positive in all patients when it was performed at least 2 days after the peak-ALT day. Conclusions: The results of HAV tests were significantly associated with the interval from the peak-ALT day to the HAV-test day. The optimal time for repeating the HAV test in clinically suspicious AHA patients with a negative initial HAV test appears to be at least 2 days after the peak-ALT day. (Korean J Hepatol 2012;18:56-62)
INTRODUCTION
Acute hepatitis A (AHA) is the most common cause of acute hepatitis in Korea. 1, 2 It usually results in a self-limited episode of acute hepatitis without chronic infection or complication. 3 The overall prognosis of AHA is excellent; about 60% of patients completely recover within 2 months and almost every affected person recovers within 6 months. 3 Diagnosis of AHA is usually made by the detection of anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in serum. IgM anti-HAV test (HAV test) have high diagnostic sensitivity and specificity of more than 99%. 4 The test result usually becomes positive at the onset of symptoms 5 and usually remains positive for approximately 4 months thereafter. 6 However, IgM anti-HAV is not detected in some patients with AHA, especially during the early phase of AHA. Previous studies suggested that initial HAV test was negative in 6.4-6.7% of patients with AHA. 7, 8 Hence,
repeating HAV test after 1-2 weeks is usually recommended in clinically suspicious AHA patients with negative initial Figure 1 . Definition of the phase of AHA. Phase I is the period from the AHA-associated symptom-onset day to the peak-ALT day. Phase II is the period from the peak-ALT day to the peak-bilirubin day. Phase III is the period after the peak-bilirubin day. ALT, alanine aminotransferase.
HAV test. Nevertheless, data to substantiate this recommendation is scarce and studies validating this suggestion are lacking. Therefore, we performed this retrospective study to evaluate the optimal time for repeating HAV test in clinically suspicious AHA patients with negative initial HAV test.
PATIENTS AND METHODS

Patients
We retrospectively reviewed the medical records of all patients with AHA who had been admitted to the Korea 
Definitions
Day 0, defined as the day of acute hepatitis-associated symptom onset, was determined by thoroughly reviewing the patients' history through medical records. Serum ALT and bilirubin (BIL) levels were repeated in each patient every 2-3 days until peak levels of all parameters were identified in all enrolled patients.
The course of AHA was classified into 3 periods as follows ( Fig. 1 ): 9 1) Phase I was defined as the period from day 0 to the day when serum ALT levels peak (peak-ALT day). The serum levels of both ALT and BIL usually increase during this period.
2) Phase II was defined as the period from the peak-ALT day to the day when serum BIL levels peak (peak-BIL day).
The serum ALT levels decrease but serum BIL levels continue to increase during this period.
3) Phase III was defined as the period after the peak-BIL day. The serum levels of both ALT and BIL decreased during this period, but have not recovered to below the upper limit of normal.
In patients who were admitted during the phase II, the admission day was assumed as the peak-ALT day, and in those who were admitted during the phase III, the admission day was assumed as both peak-ALT day and the peak-BIL day.
Statistical analysis
Statistical analyses were performed using the Statistical 
RESULTS
Baseline characteristics
A total of 261 patients with AHA were hospitalized during the study period. The mean age was 31.2±7.0 years Interval from the day 0 to hospitalization day (day) 5.3 ±2.6
Interval from the day 0 to the first HAV-test day (day) 6.3 ±2.9
Interval from peak-ALT day to the first HAV-test day (day) 0.5 ±1.7
Interval from peak-BIL day to the first HAV-test day (day) -4. Timing of the initial HAV test. At the time of the initial HAV test, about half of the patients were in phase II, and none of the patients with negative initial HAV test were in phase III. The HAV test was repeated 6.5±2.3 days (mean±SD) after the first test in these 28 patients, at which time 6 (21.4%) patients were in phase II and 22 (78.6%) were in phase III. HAV, hepatitis A virus.
and 158 patients (60.5%) were men ( Proportions of patients with negative initial HAV tests at each day from the peak-ALT day (defined as day 0). The proportion of patients with a negative initial HAV test decreased as the initial HAV test time approached the peak-ALT day, and the test for IgM anti-HAV was positive in all patients at 2 days after the peak-ALT day.
HAV test was positive in 233 (89.3%) patients, thus being diagnosed as AHA, while it was negative in 28 (10.7%) patients.
In these 28 patients, the second HAV test was done 6.5±2.3 days after the first HAV test. The interval from the peak-ALT day to the second test was 5.0±3.2 days (range, 1-16 days), while the interval from the peak-BIL day to the second test was 1.1±3.9 days (range, -9~13 days). The second HAV test was done during phase II in 6 (21.4%) patients and during phase III in 22 (78.6%) patients (Fig. 2) .
Comparison between patients with negative initial IgM anti-HAV and with positive initial IgM anti-HAV The proportion of men was greater in the negative initial IgM anti-HAV group than the positive initial IgM anti-HAV group, while the age did not differ between the two groups ( (Fig. 3) . HAV test was positive in all patients when it was performed at least 2 days after the peak-ALT day.
Subgroup analysis in patients hospitalized during the phase I of acute hepatitis A
The positivity of HAV tests were significantly related with the interval from the peak-ALT day to the HAV-test day.
However, the peak-ALT day could not be said to have represented their true peak day or their true peak levels in patients admitted during the phase II or III. Therefore, we performed a subgroup analysis with patients who were hospitalized during the phase I. Table 3 ).
DISCUSSION
Our results suggest that up to 10% of patients with symptomatic AHA cannot be diagnosed if we rely solely on the result of initial HAV test. HAV RNA assay could be an option for diagnosing AHA in patients whose HAV test is negative. HAV RNA has been detected in the serum, stool, and liver tissue using molecular hybridization assay or reverse transcription-PCR assay. 10, 11 However, the use of HAV RNA assay is still limited to research laboratories. patients. In addition, on multivariate analysis, the only significant parameter associated with the result of the initial HAV test was the duration from peak-ALT day to the initial test day. Therefore, it could be suggested that the optimal time for repeating HAV test in clinically suspicious AHA patients with negative initial HAV test would be at least 2 days after peak-ALT day.
Although previous studies have not classified and analyzed their data according to the clinical course of AHA as we have done in our study, the fact that higher proportion of patients presented with fever and abdominal pain 7 or lower ALT level and that the interval from symptom onset to hospital admission was shorter 12 in patients with negative initial HAV test suggest that, consistent with our data, initial tests had been performed during the phase I in the majority of study subjects.
When we look at Table 2 The result of our study shows that initial HAV tests were negative in 10.7% of patients with AHA, which is relatively higher than that of the previous studies (6.4-6.7%). 7, 12 Because these previous studies have not separately demonstrated the data of their patients according to the phase of AHA, it is difficult to clearly state the reason for this discrepancy on initial HAV test negativity. However, there is a possibility that higher proportion of patients could have been hospitalized during the phase I in our study.
Because symptoms during the prodromal period, including fever, chill, nausea, and abdominal pain, are too nonspecific, it is not easy for the patient to consider themselves to have AHA during this period. Therefore, most of the patients with AHA make hospital visits during the icteric period because of jaundice. In Korea, the prevalence of symptomatic AHA has increased since the AHA outbreak in 2008 13 and ever since, more people have become more aware of AHA and visit the hospital to be assessed for this condition if they have fever of chilling sensation. Consistent with this trend, the proportion of patients who visited the hospital during the prodromal period has risen and this might have led to these discrepancies in our study compared to the previous studies.
In conclusion, the result of HAV test was significantly associated with the duration from peak-ALT day to the test day. The optimal time for repeating HAV test in clinically suspicious patients with negative initial test seems to be at least 2 days after peak-ALT day.
